In contrast to ALK expression, expression of p-AKT, p-mTOR, p-4E-BP1, or p-p70S6K1 did not have any prognostic significance in ALCL; however, in vitro studies indicated that targeting the hyperactivated AKT/mTOR pathway effectively inhibited cell growth, triggered apoptosis, and reversed glucocorticoid (GC) resistance, suggesting an attractive therapeutic potential of AKT/mTOR inhibitors in ALCL. Here, RPS6KB1 is linked to anaplastic large cell lymphoma.